Isatin

Isatin

SCHEMBL973760

O=C1Nc2ccccc2C1=O.O=C1Nc2ccccc2C1=O

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAOA P21397 6/20 1.00
MAOB P27338 6/20 1.00
LRRK2 Q5S007 3/20 0.67
ACVR1 Q04771 2/20 0.67
PDGFRA P16234 1/20 0.67
FER P16591 1/20 0.67
LTK P29376 1/20 0.67
CDK8 P49336 1/20 0.67
DYRK1B Q9Y463 1/20 0.67
CASP3 P42574 1/20 0.62
CASP2 P42575 1/20 0.62
CASP7 P55210 1/20 0.62
CASP6 P55212 1/20 0.62
CASP8 Q14790 1/20 0.62
CSNK1G1 Q9HCP0 1/20 0.53
GSK3B P49841 1/20 0.52
CES1 P23141 4/20 0.52
TGM2 P21980 3/20 0.52
MAPT P10636 3/20 0.52
MEN1 O00255 2/20 0.52

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Isatin SCHEMBL34016 1.00 MAOA (1.00) MAOAMAOBLRRK2ACVR1PDGFRA
Isatin SCHEMBL2259764 0.98 MAOA (0.95) MAOAMAOBLRRK2ACVR1PDGFRA
Isatin SCHEMBL4092377 0.98 MAOA (0.95) MAOAMAOBLRRK2ACVR1PDGFRA
Isatin SCHEMBL29370079 0.98 MAOA (0.95) MAOAMAOBLRRK2ACVR1PDGFRA
Isatin SCHEMBL1590864 0.98 MAOA (0.95) MAOAMAOBLRRK2ACVR1PDGFRA
Isatin SCHEMBL23256320 0.98 MAOA (0.95) MAOAMAOBLRRK2ACVR1PDGFRA
Isatin SCHEMBL10833581 0.98 MAOA (0.95) MAOAMAOBLRRK2ACVR1PDGFRA
Isatin SCHEMBL11646710 0.98 MAOA (0.95) MAOAMAOBLRRK2ACVR1PDGFRA
Isatin SCHEMBL7061560 0.98 MAOA (0.95) MAOAMAOBLRRK2ACVR1PDGFRA
Isatin SCHEMBL29869001 0.98 MAOA (0.95) MAOAMAOBLRRK2ACVR1PDGFRA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110002877-A1 PTEN Inhibitors Treat Neutropenia-Associated Pneumonia CHILDREN'S MEDICAL CENTER CORPORATION 2011-01-06 US claimed
JP-10338693-A None JP disclosed
WO-2023179922-A1 AGENT FOR OXIDATIVE DYEING OF KERATIN FIBRES, CONTAINING ISATIN AND AT LEAST ONE DEFINED POLYMER HENKEL AG & CO. KGAA (DE) 2023-09-28 WO disclosed
CN-108853102-A Act on the condensed acridine derivatives and application thereof of Dectin-1 北京大学 2018-11-23 CN disclosed
US-8871718-B2 Transglutaminase inhibitors and methods of use thereof THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) 2014-10-28 US disclosed
US-8470782-B2 Transglutaminase inhibitors and methods of use thereof THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) 2013-06-25 US disclosed
US-20130102633-A1 TRANSGLUTAMINASE INHIBITORS AND METHODS OF USE THEREOF THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) 2013-04-25 US disclosed
US-8153593-B2 Transglutaminase inhibitors and methods of use thereof THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) 2012-04-10 US disclosed
CN-102358729-A 3-hydroxy- indol-2-one derivatives, anti-plant virus disease drugs adopting 3-hydroxy-indol-2-one derivatives as active ingredients, and application thereof KUNMING INST BOTANY CN ACAD 2012-02-22 CN disclosed
US-20110286995-A1 Drug Therapy for Celiac Sprue THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY 2011-11-24 US disclosed
US-20080044401-A1 DRUG THERAPY FOR CELIAC SPRUE THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY 2008-02-21 US disclosed
US-20070251025-A1 Hair coloring kits and methods of use thereof THE PROCTER & GAMBLE COMPANY 2007-11-01 US disclosed
US-7265093-B2 Drug therapy for Celiac Sprue THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) 2007-09-04 US disclosed
WO-2007025247-A2 TRANSGLUTAMINASE INHIBITORS AND METHODS OF USE THEREOF THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) 2007-03-01 WO disclosed
WO-2007010201-A2 MEDICAL DEVICES AND COATINGS THEREFOR ASTON UNIVERSITY (GB) 2007-01-25 WO disclosed
EP-1706129-A1 DRUG THERAPY FOR CELIAC SPRUE The Board of Trustees of The Leland Stanford Junior University (US) 2006-10-04 EP disclosed
US-20060052308-A1 Administering to a patient an effective dose of [(S)-1-[(3-Bromo-4,5-dihydro-isoxazol-5-ylmethyl)-methyl-carbamoyl]-2-(4-hydroxy-phenyl)-ethyl]-carbamic acid benzyl ester; treatment of glioblastoma, meningioma, melanoma and colon cancer THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY 2006-03-09 US disclosed
WO-2005049064-A1 DRUG THERAPY FOR CELIAC SPRUE THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) 2005-06-02 WO disclosed
US-20040167069-A1 Drug therapy for Celiac Sprue NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2004-08-26 US disclosed
JP-H10338693-A ISATIN DERIVATIVE NIPPON ZOKI PHARMACEUT CO LTD 1998-12-22 JP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080044401-A1 DRUG THERAPY FOR CELIAC SPRUE SI, DNPEP, SPINT2 MAOA 3071/4885MAOB 2372/4885LRRK2 3709/4885
US-20110002877-A1 PTEN Inhibitors Treat Neutropenia-Associated Pneumonia CSF3R, CSF1R, ATM MAOA 4736/4885MAOB 4745/4885LRRK2 677/4885
US-20130102633-A1 TRANSGLUTAMINASE INHIBITORS AND METHODS OF USE THEREOF TGM2, TGM3, TGM1 MAOA 436/4885MAOB 267/4885LRRK2 3008/4885
US-20110286995-A1 Drug Therapy for Celiac Sprue SI, DNPEP, SPINT2 MAOA 3071/4885MAOB 2372/4885LRRK2 3709/4885
US-20060052308-A1 Administering to a patient an effective dose of [(S)-1-[(3-Bromo-4,5-dihydro-isoxazol-5-ylmethyl)-methyl-carbamoyl]-2-(4-hydroxy-phenyl)-ethyl]-carbamic acid benzyl ester; treatment of glioblastoma, meningioma, melanoma and colon cancer MGMT, GMFG, HNMT MAOA 599/4885MAOB 473/4885LRRK2 3819/4885
US-20040167069-A1 Drug therapy for Celiac Sprue SI, DNPEP, SPINT2 MAOA 3071/4885MAOB 2372/4885LRRK2 3709/4885
US-20070251025-A1 Hair coloring kits and methods of use thereof COXFA4L2, SQOR, GPX4 MAOA 192/4885MAOB 193/4885LRRK2 4751/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.